Literature DB >> 155781

Growth hormone hyperresponsiveness to dopaminergic stimulation in Huntington's chorea.

E E Müller, E A Parati, A E Panerai, D Cocchi, T Caraceni.   

Abstract

The effect of 3 dopamine (DA) mimetic drugs, i.e. bromocriptine (Bro), apomorphine (Apo) and L-3,4-Dihydroxpenylalanine (L-dopa), was evaluated on plasma growth hormone (GH) levels in 18 patients with Huntington's chorea (HC). 27 Nonobese hospitalized patients were used as controls. Mean baseline GH levels were not altered in patients with HC. Oral administration of Bro (2.5 mg po) or L-dopa (500 mg), or subcutaneous administration of Apo (1.0 mg) resulted in a significantly greater and more prompt (Bro, L-dopa) increase in plasma GH in patients than in controls. These results suggest that presence of an altered dopaminergic regulation of GH secretion in HC.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 155781     DOI: 10.1159/000122878

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  5 in total

1.  Piperine Enhances the Protective Effect of Curcumin Against 3-NP Induced Neurotoxicity: Possible Neurotransmitters Modulation Mechanism.

Authors:  Shamsher Singh; Sumit Jamwal; Puneet Kumar
Journal:  Neurochem Res       Date:  2015-07-10       Impact factor: 3.996

2.  Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.

Authors:  Mahmoud A Pouladi; Yuanyun Xie; Niels Henning Skotte; Dagmar E Ehrnhoefer; Rona K Graham; Jeong Eun Kim; Nagat Bissada; X William Yang; Paolo Paganetti; Robert M Friedlander; Blair R Leavitt; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2010-01-22       Impact factor: 6.150

3.  Neuroendocrine effects of quipazine in man in health state or with neurological disorders.

Authors:  E A Parati; P Zanardi; D Cocchi; T Caraceni; E E Müller
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

4.  Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease.

Authors:  R Durso; C A Tamminga; S Ruggeri; A Denaro; S Kuo; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-12       Impact factor: 10.154

5.  Effects of DA agonist in Huntington disease hyperkinesia.

Authors:  T A Caraceni; F Girotti; P Giovannini; M Pederzoli; E A Parati
Journal:  Ital J Neurol Sci       Date:  1980-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.